Home / Learn / Precision Medicine / Treatment / Bispecific Antibodies / Successful Integration of Bispecific Antibodies into Community Oncology Practice

Successful Integration of Bispecific Antibodies into Community Oncology Practice

Bispecific antibodies, designed to redirect immune cells to target specific cancer cells or to simultaneously block two different pathways involved in disease, have far-reaching therapeutic potential as treatment for cancer.

The Association of Cancer Care Centers (ACCC)—in partnership with the Lymphoma Research Foundation and the Advanced Practitioner Society for Hematology and Oncology (APSHO)—has launched an educational initiative to prepare cancer care teams for the successful integration of bispecific antibodies into community oncology settings and to help care teams assess readiness for the safe administration and use of bispecific antibodies, including management of adverse events associated with bispecific antibodies. This program also explores best practices in care coordination, including the importance of establishing strong referral networks between academic and community sites as well as process improvements to optimize referral patterns, navigation and patient advocacy services, and transitions of care for patients receiving bispecific antibodies.

This project was made possible by support from Genentech and Johnson and Johnson.

Featured Resources

Resource Library

Access a collection of curated tools and resources to assist cancer programs with the integration of bispecific antibodies into community oncology practice. Explore training for the multidisciplinary care team, consensus recommendations, and policy and procedure information.
Learn More

A Blueprint for Successful Integration of Bispecific Antibodies

Explore a quick guide developed to support the operationalization of bispecific antibodies (BsAbs) in the community oncology setting. Receive suggestions for how each member of the multidisciplinary care team can be involved in building organizational capacity to treat eligible patients with BsAbs.
Download Now

From the ACCCBuzz Blog

Where to Start? Implementing Bispecific Antibody Therapies in the Community Setting
December 18, 2024
ACCC spoke to Kelly Terrell to capture her insights and tips for community cancer centers to get started with providing bispecific antibody therapies to patients with cancer.
Addressing Myths and Building Confidence Towards Delivering Bispecific Antibodies in the Community Setting
November 27, 2024
ACCCBuzz spoke to Joshua Brody, MD to better understand how Bispecific Antibodies work and how they can be easily implemented in the community setting.
Supporting Patient Information and Resource Needs for Bispecific Antibody Treatments
November 05, 2024
ACCC is committed to helping cancer care team members, patients, and caregivers understand how bispecific antibody treatments fit within the cancer care continuum, how they differ from CAR T-cell therapy, and the education and resources available to patients and their families.

CANCER BUZZ Podcast

Exploring Bispecific Antibodies in Community Oncology: Overcoming Challenges and Harnessing Opportunities – [Video Podcast] Ep 52
In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices.

Navigating the Operational Challenges of Treatment with Bispecific Antibodies - [Podcast] Ep 148
Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at WVU Cancer Institute who discusses the challenges of care coordination and therapy and shares operational best practices for the delivery of bispecific antibodies in the community setting.

From Oncology Issues

Readiness for Bispecific Antibody Therapy: Initiation and Maintenance Phases

Explore insights gained from a landscape analysis and focus group discussions detailing how community oncology programs can address barriers, build capacity, raise awareness, and embrace collaboration to integrate BsAb therapy into clinical practice.
Download Now

Abstract Presentation

[Abstract 2289] Demystifying the delivery and adverse event management of bispecific antibodies in the community setting

December 7, 2024
Accepted for poster presentation at the American Society of Hematology 2024 Annual Meeting,
December 6 – 9, 2024
View Abstract

Share

In This Section